معرفی
Richard Dunne, M.D., M.S. is an Associate Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He is a practicing medical oncologist at the Wilmot Cancer Institute specializing in gastrointestinal cancers, particularly pancreatic and hepatobiliary malignancies, with a strong research focus on cancer cachexia and weight loss in cancer patients.
- MS, University of Rochester, 2021
- MD, SUNY Downstate Health Sciences University - College of Medicine, 2009
- Internship, Internal Medicine, University of Rochester Medical Center, 2009-2010
- Residency, Internal Medicine, University of Rochester Medical Center, 2010-2012
- Fellowship, Hematology & Oncology, University of Rochester Medical Center, 2013-2015
- Fellowship, Research, University of Rochester Medical Center, 2016-2019
Dr. Dunne's research primarily focuses on cancer cachexia (muscle wasting associated with cancer) and weight loss trajectories in advanced cancer patients. He has particular expertise in pancreatic and hepatobiliary cancers, with numerous publications examining the relationship between body composition, nutritional status, and outcomes in these malignancies. His work also extends to organ preservation strategies in rectal cancer and the use of targeted therapies for biliary tract cancers. As a clinical researcher, he leads several trials focused on improving outcomes for patients with gastrointestinal malignancies and cancer-related wasting syndromes.
Dr. Dunne's recent publications (2024-2025) demonstrate a strong focus on cancer cachexia, with multiple papers examining weight loss trajectories, nutritional impairment, and muscle wasting across various cancer types. He has made significant contributions to the field of biliary tract cancers, particularly regarding the use of targeted therapies like pemigatinib for FGFR2-rearranged cholangiocarcinoma. His work also spans rectal cancer management, with research on organ preservation strategies and MRI predictors of treatment response. A notable trend is his multidisciplinary approach, collaborating with transplant surgeons, radiologists, nutritionists, and geriatric oncologists to address complex challenges in cancer care.
- Cancer Grand Challenges: Understand and Reverse Cachexia (2022-2027)
- Solid Tumor Faculty Leader in clinical trial accrual (2020-2021)
- CTSI KL2 Career Development Award (2019-2021)
- Department of Medicine Research Pilot Grant Award (2017-2018)
- NIH R25 Fellowship Training Program in Cancer Control (2016-2019)
- Wilmot Foundation for Cancer Research Fellowship Award (2015-2018)
Dr. Dunne serves as a lead researcher for multiple clinical trials, including an open-label Phase 1 study evaluating SX-682 in combination with nivolumab for metastatic pancreatic cancer. His research is supported by significant funding, including the Cancer Grand Challenges grant focused on understanding and reversing cachexia. He has received career development support through the CTSI KL2 program and has been recognized as a Solid Tumor Faculty Leader for clinical trial accrual. His work bridges clinical care and research, with a focus on translating findings into improved patient outcomes.
Dr. Dunne is part of the Wilmot Cancer Institute at the University of Rochester Medical Center, where he collaborates with multidisciplinary teams including medical oncologists, surgeons, radiologists, pathologists, and nutrition specialists. He works closely with transplant surgeons on innovative approaches to liver transplantation for patients with primary and metastatic liver cancers. His research involves collaborations with the Cancer Control and Survivorship program, Geriatric Oncology team, and the Translational Research Laboratory at Wilmot.
